Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
Not Recruiting
18 years - 99 years
All
Phase
3
1 Location
Brief description of study
Pleae refer to Section 3 (Objectives and Endpoints) of the full protocol Please refer to Section 3.1 (Primary Endpoint) of the full protocol Please refer to Section 3.2 (Secondary Endpoints) of the full protocol
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Acute Myeloid Leukemia
-
Age: 18 years - 99 years
-
Gender: All
Updated on
11 Sep 2024.
Study ID: 844820
